| Authors: |
Kamboj I; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Collaborative Opportunities for Research, Training, and Excellence in Innovation (CORTEX), Westwood, KC. Electronic address: i.ishitakamboj@gmail.com., Habib A; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Chang D; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC., Rashid A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Vegel A; Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA., Graf K; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology Oncology, Medical University of South Carolina, Charleston, SC., Struble E; Division of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA., Mushtaq MU; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Mahmoudjafari Z; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Green K; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology Oncology, Medical University of South Carolina, Charleston, SC., Khan AM; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Strouse CS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA., McGuirk JP; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Hashmi H; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology Oncology, Medical University of South Carolina, Charleston, SC; Division of Hematology-oncology, Memorial Sloan Kettering Cancer Center, New York City, NY., Shaikh H; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA., Atrash S; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC., Abdallah AO; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Ahmed N; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Collaborative Opportunities for Research, Training, and Excellence in Innovation (CORTEX), Westwood, KC. |
